On January 7, 2013, DexCom, Inc. announced that Kevin Sayer, currently the company's President, will assume the additional role of Chief Operating Officer. As President, Mr. Sayer is responsible for the company's research and development, manufacturing, clinical, regulatory and finance functions. Mr. Sayer will continue to lead those groups, and with the additional role of COO, Mr. Sayer will also lead DexCom's sales, marketing, and other core commercial functions. Mr. Sayer will continue to report to Mr. Gregg.

The company expects unaudited product revenues of approximately $31.6 million for the fourth quarter of 2012, up approximately 50% sequentially from the prior quarter and up approximately 51% from the fourth quarter of 2011.

The company estimated unaudited product revenue for fiscal year 2012 of approximately $92.8 million, up approximately 41% from fiscal year 2011.

In addition, the company expects fiscal year 2013 product revenue of $120.0 million - $130.0 million.